Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Excretion of [¹⁴C]Etelcalcetide in ESRD Patients
NCT02054572Phase 1Completed
- Sponsor
- Amgen
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoints: Cumulative Excretion of Radioactivity, Time to Maximum Observed Concentration and 4 more. Started Feb 2014; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02054572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054572.